** Shares of biotech firm Trinity Biotech TRIB.O rise ~56% to $1.18
** TRIB says its next-generation continuous glucose monitoring (CGM) system showed superior signal quality, enhanced reliability and breakthrough accuracy compared to previous sensors
** CGM is for people with Type 1 and Type 2 diabetes aged 18 years and older
** Co plans to file for regulatory approval in EU in 2025 and in U.S. in 2026
** TRIB fell 60% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.